You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSomatropin recombinant
Accession NumberDB00052  (BTD00086, BIOD00086)
TypeBiotech
GroupsApproved, Investigational
Description

Recombinant human growth hormone (somatotropin) 191 residues, MW 22.1 kD, synthesized in E. coli

Protein structureDb00052
Related Articles
Protein chemical formulaC990H1532N262O300S7
Protein average weight22129.0 Da
Sequences
>DB00052 sequence
FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPT
PSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEG
IQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIV
QCRSVEGSCGF
Download FASTA Format
Synonyms
GH
GH-N
Growth hormone
Growth hormone 1
Pituitary growth hormone
Somatotropin precursor
Somatropin
Somatropin [rDNA origin]
External Identifiers Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
GenotropinkitPharmacia and Upjohn Company1995-12-202016-04-23Us
Genotropinpowder for solution0.2 mgsubcutaneousPfizer Canada IncNot applicableNot applicableCanada
Genotropinpowder for solution1.6 mgsubcutaneousPfizer Canada Inc2013-09-18Not applicableCanada
Genotropinpowder for solution0.4 mgsubcutaneousPfizer Canada IncNot applicableNot applicableCanada
GenotropinkitPharmacia and Upjohn Company1995-12-202016-04-23Us
GenotropinkitPharmacia and Upjohn Company1995-12-202016-04-23Us
Genotropinpowder for solution5 mgsubcutaneousPfizer Canada IncNot applicableNot applicableCanada
Genotropinpowder for solution1.4 mgsubcutaneousPfizer Canada Inc2013-09-18Not applicableCanada
GenotropinkitPharmacia and Upjohn Company1995-12-202016-04-23Us
GenotropinkitPharmacia and Upjohn Company1995-12-202016-04-23Us
Genotropinpowder for solution1.2 mgsubcutaneousPfizer Canada Inc2013-09-18Not applicableCanada
Genotropinpowder for solution1.0 mgsubcutaneousPfizer Canada Inc2013-09-18Not applicableCanada
GenotropinkitPharmacia and Upjohn Company1995-12-202016-04-23Us
GenotropinkitPharmacia and Upjohn Company1995-12-202016-04-23Us
Genotropinpowder for solution0.8 mgsubcutaneousPfizer Canada Inc2013-09-18Not applicableCanada
GenotropinkitPharmacia and Upjohn Company1995-12-202016-04-23Us
GenotropinkitPharmacia and Upjohn Company1995-12-202016-04-23Us
Genotropinpowder for solution0.6 mgsubcutaneousPfizer Canada Inc2013-09-18Not applicableCanada
GenotropinkitPharmacia and Upjohn Company1995-12-202016-04-23Us
GenotropinkitPharmacia and Upjohn Company1995-12-202016-04-23Us
Genotropinpowder for solution2.0 mgsubcutaneousPfizer Canada Inc2013-09-18Not applicableCanada
Genotropinpowder for solution12 mgsubcutaneousPfizer Canada Inc2013-09-18Not applicableCanada
GenotropinkitPharmacia and Upjohn Company1995-12-202016-04-23Us
Genotropinpowder for solution1.8 mgsubcutaneousPfizer Canada Inc2013-09-18Not applicableCanada
Genotropinpowder for solution5.3 mgsubcutaneousPfizer Canada Inc2013-09-18Not applicableCanada
Humatropekitintramuscular; subcutaneousEli Lilly and Company1987-04-012016-04-23Us
Humatropekitintramuscular; subcutaneousEli Lilly and Company2006-01-272016-04-23Us
Humatropekitintramuscular; subcutaneousEli Lilly and Company2006-01-272016-04-23Us
Humatropekitintramuscular; subcutaneousEli Lilly and Company2006-01-272016-04-23Us
Humatrope Inj 1mg/mlpowder for solution1 mgintramuscular; subcutaneousEli Lilly Canada Inc1987-12-31Not applicableCanada
Norditropininjection, solution5 mg/1.5mLsubcutaneousNovo Nordisk2005-01-032016-04-23Us
Norditropininjection, solution30 mg/3mLsubcutaneousNovo Nordisk2009-03-302016-04-23Us
Norditropininjection, solution5 mg/1.5mLsubcutaneousPhysicians Total Care, Inc.2010-08-102016-04-05Us
Norditropininjection, solution15 mg/1.5mLsubcutaneousNovo Nordisk2005-01-032016-04-23Us
Norditropininjection, solution10 mg/1.5mLsubcutaneousNovo Nordisk2006-01-022016-04-23Us
Norditropin Nordiflexsolution10 mgsubcutaneousNovo Nordisk Canada Inc2014-08-15Not applicableCanada
Norditropin Nordiflexsolution15 mgsubcutaneousNovo Nordisk Canada Inc2014-08-15Not applicableCanada
Norditropin Nordiflexsolution5 mgsubcutaneousNovo Nordisk Canada Inc2014-08-15Not applicableCanada
Norditropin Simplexxsolution5 mgsubcutaneousNovo Nordisk Canada Inc2010-05-042015-06-19Canada
Norditropin Simplexxsolution10 mgsubcutaneousNovo Nordisk Canada Inc2010-05-042015-06-19Canada
Norditropin Simplexxsolution15 mgsubcutaneousNovo Nordisk Canada Inc2010-05-042015-06-19Canada
NutropinkitGenentech, Inc.1993-11-172015-12-29Us
NutropinkitGenentech, Inc.1993-11-172015-12-29Us
Nutropin AQ - Sc 5mg/mlliquid5 mgsubcutaneousHoffmann La Roche Limited1997-10-142013-04-16Canada
Nutropin AQ Nuspin 10solution10 mgsubcutaneousHoffmann La Roche Limited2012-05-18Not applicableCanada
Nutropin AQ Nuspin 10injection, solution10 mg/2mLsubcutaneousGenentech, Inc.1995-12-292016-04-05Us
Nutropin AQ Nuspin 20injection, solution20 mg/2mLsubcutaneousGenentech, Inc.1995-12-292016-04-05Us
Nutropin AQ Nuspin 20solution20 mgsubcutaneousHoffmann La Roche Limited2013-09-09Not applicableCanada
Nutropin AQ Nuspin 5solution5 mgsubcutaneousHoffmann La Roche Limited2013-09-09Not applicableCanada
Nutropin AQ Nuspin 5injection, solution5 mg/2mLsubcutaneousGenentech, Inc.1995-12-292016-04-05Us
Nutropin AQ Pen 10injection, solution10 mg/2mLsubcutaneousGenentech, Inc.1995-12-292016-04-05Us
Nutropin AQ Pen 20injection, solution20 mg/2mLsubcutaneousGenentech, Inc.1995-12-292016-04-05Us
Nutropin AQ Pen Cartridgesolution10 mgsubcutaneousHoffmann La Roche Limited2004-08-09Not applicableCanada
Omnitropesolution5.0 mgsubcutaneousSandoz Canada Incorporated2009-04-20Not applicableCanada
OmnitropekitSandoz Inc2006-05-302016-04-05Us
Omnitropeinjection, solution10 mg/1.5mLsubcutaneousSandoz Inc2006-05-302016-04-05Us
Omnitropeinjection, solution5 mg/1.5mLsubcutaneousSandoz Inc2006-05-302016-04-05Us
Omnitropesolution10.0 mgsubcutaneousSandoz Canada Incorporated2009-04-20Not applicableCanada
Saizensolution8 mgsubcutaneousEmd Serono A Division Of Emd Inc Canada2010-12-02Not applicableCanada
Saizensolution8 mgsubcutaneousEmd Serono A Division Of Emd Inc Canada2010-12-02Not applicableCanada
Saizenpowder for solution5 mgintramuscular; subcutaneousEmd Serono A Division Of Emd Inc Canada1999-10-26Not applicableCanada
Saizensolution5.83 mgsubcutaneousEmd Serono A Division Of Emd Inc Canada2010-12-02Not applicableCanada
Saizenkitintramuscular; subcutaneousEMD Serono, Inc.2000-08-292016-04-05Us
Saizenkitintramuscular; subcutaneousEMD Serono, Inc.1996-10-082016-04-05Us
Saizen 8.8mg (5.83mg/ml)powder for solution8.8 mgsubcutaneousEmd Serono A Division Of Emd Inc Canada2006-01-23Not applicableCanada
Saizen Clickeasykitintramuscular; subcutaneousEMD Serono, Inc.2004-07-092016-04-05Us
SerostimkitsubcutaneousEMD Serono, Inc.1996-08-232016-04-05Us
SerostimkitsubcutaneousEMD Serono, Inc.1996-08-232016-04-05Us
SerostimkitsubcutaneousEMD Serono, Inc.1997-07-252016-04-05Us
ZomactonkitsubcutaneousFerring Pharmaceuticals Inc.2015-03-012016-04-05Us
ZomactonkitFerring Pharmaceuticals Inc.1995-05-252016-04-05Us
Generic Prescription ProductsNot Available
Over the Counter ProductsNot Available
International Brands
NameCompany
BioTropinBiotech General
NutropinAQGenentech Inc.
Brand mixtures
NameLabellerIngredients
Bio-tropinNovopharm Limited
Nutropin - Kit Pws(10mg) & Liq(10ml) Im ScHoffmann La Roche Limited
Nutropin - Kit Pws(5mg) & Liq(10ml) Im ScHoffmann La Roche Limited
OmnitropeSandoz Canada Incorporated
Saizen 10iu - KitEmd Serono A Division Of Emd Inc Canada
SerostimEmd Serono A Division Of Emd Inc Canada
SaltsNot Available
Categories
UNIINQX9KB6PCL
CAS number12629-01-5
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationFor treatment of dwarfism, acromegaly and prevention of HIV-induced weight loss
PharmacodynamicsUsed in the treatment of dwarfism and growth failure, growth hormone (hGH) stimulates skeletal growth in pediatric patients with growth failure due to a lack of adequate secretion of endogenous GH. Skeletal growth is accomplished at the epiphyseal plates at the ends of a growing bone. Growth and metabolism of epiphyseal plate cells are directly stimulated by GH and one of its mediators, IGF-I (insulin-like growth factor).
Mechanism of actionhGH binds to the human growth hormone receptor (GHR). Upon binding, hGH causes dimerization of GHR, activation of the GHR-associated JAK2 tyrosine kinase, and tyrosyl phosphorylation of both JAK2 and GHR. These events recruit and/or activate a variety of signaling molecules, including MAP kinases, insulin receptor substrates, phosphatidylinositol 3' phosphate kinase, diacylglycerol, protein kinase C, intracellular calcium, and Stat transcription factors. These signaling molecules contribute to the GH-induced changes in enzymatic activity, transport function, and gene expression that ultimately culminate in changes in growth and metabolism.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationAlthough calcium excretion in the urine is increased, there is a simultaneous increase in calcium absorption from the intestine. Somatropin stimulates the synthesis of chondroitin sulfate and collagen, and increases the urinary excretion of hydroxyproline.
Half lifeNot Available
Clearance
  • 2.3 +/- 1.8 mL/min/kg [GHD patients (IV 33 ng/kg/min)]
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
Manufacturers
  • Genentech inc
  • Serono laboratories inc
  • Cangene corp
  • Ferring pharmaceuticals inc
  • Pharmacia and upjohn co
  • Eli lilly and co
  • Novo nordisk inc
  • Sandoz inc
  • Emd serono inc
  • Lg life sciences ltd
Packagers
Dosage forms
FormRouteStrength
Liquid; powder for solutionsubcutaneous
Kit
Powder for solutionsubcutaneous0.2 mg
Powder for solutionsubcutaneous0.4 mg
Powder for solutionsubcutaneous0.6 mg
Powder for solutionsubcutaneous0.8 mg
Powder for solutionsubcutaneous1.0 mg
Powder for solutionsubcutaneous1.2 mg
Powder for solutionsubcutaneous1.4 mg
Powder for solutionsubcutaneous1.6 mg
Powder for solutionsubcutaneous1.8 mg
Powder for solutionsubcutaneous12 mg
Powder for solutionsubcutaneous2.0 mg
Powder for solutionsubcutaneous5 mg
Powder for solutionsubcutaneous5.3 mg
Kitintramuscular; subcutaneous
Powder for solutionintramuscular; subcutaneous1 mg
Injection, solutionsubcutaneous10 mg/1.5mL
Injection, solutionsubcutaneous15 mg/1.5mL
Injection, solutionsubcutaneous30 mg/3mL
Injection, solutionsubcutaneous5 mg/1.5mL
Solutionsubcutaneous15 mg
Kit; powder for solutionintramuscular; subcutaneous
Liquidsubcutaneous5 mg
Solutionsubcutaneous20 mg
Injection, solutionsubcutaneous5 mg/2mL
Solutionsubcutaneous5 mg
Injection, solutionsubcutaneous10 mg/2mL
Injection, solutionsubcutaneous20 mg/2mL
Solutionsubcutaneous10 mg
Kit; powder for solutionsubcutaneous
Solutionsubcutaneous10.0 mg
Solutionsubcutaneous5.0 mg
Powder for solutionintramuscular; subcutaneous5 mg
Solutionsubcutaneous5.83 mg
Solutionsubcutaneous8 mg
Powder for solutionintramuscular; subcutaneous
Powder for solutionsubcutaneous8.8 mg
Kitsubcutaneous
Powder for solutionsubcutaneous
Prices
Unit descriptionCostUnit
Humatrope 24 mg cartridge1822.9USD cartridge
Norditropin flexpro 15 mg/1.51179.54USD ml
Norditropin 15 mg/1.5ml Solution 1.5ml Cartridge1168.32USD cartridge
Norditropin NordiFlex Pen 15 mg/1.5ml Solution 1 Syringe = 1.5ml1168.32USD pen
Norditropin 15 mg/1.5 ml cartridge1123.38USD ml
Norditropin nordiflx 15 mg/1.51123.38USD ml
Genotropin 12 mg Solution928.36USD each
Humatrope 12 mg cartridge911.45USD cartridge
Nutropin 10 mg vial784.7USD vial
Nutropin aq 20 mg/2ml pen cart759.55USD ml
Nutropin aq nuspin 20 pen cart759.55USD ml
Norditropin NordiFlex Pen 10 mg/1.5ml Solution 1 Syringe = 1.5ml753.86USD pen
Norditropin nordiflex 30 mg/3748.92USD ml
Saizen 8.8 mg Solution Vial626.1USD vial
Saizen Click.Easy 8.8 mg Solution Vial626.1USD vial
Saizen 8.8 mg vial602.02USD vial
Protropin 10 mg Solution Vial549.9USD vial
Humatrope 6 mg cartridge455.72USD cartridge
Genotropin MiniQuick 0.8 mg (7 Cartridges Per Box)433.56USD box
Serostim 8.8 mg vial418.66USD vial
Nutropin 5 mg vial392.35USD vial
Saizen 5 mg Solution Vial391.31USD vial
Genotropin 5.8 mg Cartridge391.21USD cartridge
Norditropin 5 mg/1.5ml Solution 1.5ml Cartridge389.44USD cartridge
Norditropin NordiFlex Pen 5 mg/1.5ml Solution 1 Syringe = 1.5ml389.44USD pen
Saizen 5 mg vial376.26USD vial
Serostim 6 mg vial332.86USD vial
Genotropin MiniQuick 0.6 mg (7 Cartridges Per Box)326.67USD box
Omnitrope 5.8 mg Solution Vial283.38USD vial
Serostim 5 mg vial277.38USD vial
Protropin 5 mg Solution Vial274.95USD vial
Tev-Tropin 5 mg Solution Vial259.45USD vial
Tev-tropin 5 mg vial239.51USD vial
Genotropin MiniQuick 0.4 mg (7 Cartridges Per Box)228.45USD box
Serostim 4 mg vial221.9USD vial
Genotropin MiniQuick 2 mg (7 Cartridges Per Box)154.72USD cartridge
Genotropin miniquick 2 mg150.46USD each
Genotropin miniquick 1.8 mg135.41USD each
Genotropin MiniQuick 1.6 mg (7 Cartridges Per Box)123.78USD cartridge
Genotropin miniquick 1.6 mg120.37USD each
Genotropin MiniQuick 0.2 mg (7 Cartridges Per Box)110.52USD box
Genotropin MiniQuick 1.4 mg (7 Cartridges Per Box)108.78USD cartridge
Genotropin miniquick 1.4 mg105.32USD each
Genotropin MiniQuick 1.2 mg (7 Cartridges Per Box)92.83USD cartridge
Genotropin miniquick 1.2 mg90.28USD each
Genotropin MiniQuick 1 mg (7 Cartridges Per Box)77.36USD cartridge
Genotropin miniquick 1 mg75.23USD each
Genotropin miniquick 0.8 mg60.19USD each
Genotropin miniquick 0.6 mg45.14USD each
Genotropin miniquick 0.4 mg30.09USD each
Genotropin miniquick 0.2 mg15.05USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1326439 No1994-01-252011-01-25Canada
CA2252535 No2009-06-232017-04-24Canada
US5288703 No1994-10-072011-10-07Us
US5849700 No1995-12-152015-12-15Us
US5849704 No1995-12-152015-12-15Us
US5898030 No1996-04-272016-04-27Us
US6004297 No1999-01-282019-01-28Us
US6152897 No1998-11-202018-11-20Us
US6235004 No1999-01-282019-01-28Us
US6899699 No2002-01-022022-01-02Us
US7686786 No2006-08-032026-08-03Us
US8672898 No2002-01-022022-01-02Us
US8684969 No2005-10-202025-10-20Us
US8841252 No1997-12-262017-12-26Us
US8920383 No2006-07-172026-07-17Us
US9108002 No2006-01-202026-01-20Us
US9132239 No2012-02-012032-02-01Us
USRE41956 No2001-01-212021-01-21Us
USRE43834 No1999-01-282019-01-28Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point76 °C at pH 3.5Gomez-Orellana, I. et al., Protein Sci. 7:1352-1358 (1998)
hydrophobicity-0.411Not Available
isoelectric point5.27Not Available
References
Synthesis Reference

Mandayam J. Narasimhan, John A. Anderson, “Process for the large scale production of human growth hormone by serial secondary suspension culture.” U.S. Patent US4124448, issued January, 1963.

US4124448
General References
  1. Seltzer V, Tonge SR: Proceedings: Methylamphetamine withdrawal as a model for the depressive state: antagonism of post-amphetamine depression by imipramine. J Pharm Pharmacol. 1975 Dec;27 Suppl?-2:16P. [PubMed:2688 ]
  2. Alba-Roth J, Muller OA, Schopohl J, von Werder K: Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. J Clin Endocrinol Metab. 1988 Dec;67(6):1186-9. [PubMed:2903866 ]
  3. Scarth JP: Modulation of the growth hormone-insulin-like growth factor (GH-IGF) axis by pharmaceutical, nutraceutical and environmental xenobiotics: an emerging role for xenobiotic-metabolizing enzymes and the transcription factors regulating their expression. A review. Xenobiotica. 2006 Feb-Mar;36(2-3):119-218. [PubMed:16702112 ]
  4. Takahashi Y, Kipnis DM, Daughaday WH: Growth hormone secretion during sleep. J Clin Invest. 1968 Sep;47(9):2079-90. [PubMed:5675428 ]
External Links
ATC CodesH01AC01
AHFS CodesNot Available
PDB Entries
FDA labelDownload (241 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
Cortisone acetateThe therapeutic efficacy of Cortisone acetate can be decreased when used in combination with Somatropin recombinant.
EstradiolThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Estradiol.
EstropipateThe therapeutic efficacy of Somatropin recombinant can be decreased when used in combination with Estropipate.
PrednisoneThe therapeutic efficacy of Prednisone can be decreased when used in combination with Somatropin recombinant.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
binder
General Function:
Protein kinase binding
Specific Function:
Receptor for pituitary gland growth hormone involved in regulating postnatal body growth. On ligand binding, couples to the JAK2/STAT5 pathway (By similarity).The soluble form (GHBP) acts as a reservoir of growth hormone in plasma and may be a modulator/inhibitor of GH signaling.Isoform 2 up-regulates the production of GHBP and acts as a negative inhibitor of GH signaling.
Gene Name:
GHR
Uniprot ID:
P10912
Molecular Weight:
71498.885 Da
References
  1. Walenkamp MJ, Wit JM: Genetic disorders in the growth hormone - insulin-like growth factor-I axis. Horm Res. 2006;66(5):221-30. [PubMed:16917171 ]
  2. Wu XY, Xu Z, Chen C, Liu FK, Li JS: [Correlation of growth hormone receptor expression to preoperative radiosensitivity of rectal cancer patients]. Ai Zheng. 2006 Sep;25(9):1162-7. [PubMed:16965663 ]
  3. Adriani M, Garbi C, Amodio G, Russo I, Giovannini M, Amorosi S, Matrecano E, Cosentini E, Candotti F, Pignata C: Functional interaction of common gamma-chain and growth hormone receptor signaling apparatus. J Immunol. 2006 Nov 15;177(10):6889-95. [PubMed:17082603 ]
  4. Choi JH, Kim HS, Kim SH, Yang YR, Bae YS, Chang JS, Kwon HM, Ryu SH, Suh PG: Phospholipase Cgamma1 negatively regulates growth hormone signalling by forming a ternary complex with Jak2 and protein tyrosine phosphatase-1B. Nat Cell Biol. 2006 Dec;8(12):1389-97. Epub 2006 Nov 26. [PubMed:17128263 ]
  5. Bernstein RM, Leigh SR, Donovan SM, Monaco MH: Hormones and body size evolution in papionin primates. Am J Phys Anthropol. 2007 Feb;132(2):247-60. [PubMed:17133434 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Protein homodimerization activity
Specific Function:
This is a receptor for the anterior pituitary hormone prolactin (PRL). Acts as a prosurvival factor for spermatozoa by inhibiting sperm capacitation through suppression of SRC kinase activation and stimulation of AKT. Isoform 4 is unable to transduce prolactin signaling. Isoform 6 is unable to transduce prolactin signaling.
Gene Name:
PRLR
Uniprot ID:
P16471
Molecular Weight:
69505.045 Da
References
  1. Keeler C, Jablonski EM, Albert YB, Taylor BD, Myszka DG, Clevenger CV, Hodsdon ME: The kinetics of binding human prolactin, but not growth hormone, to the prolactin receptor vary over a physiologic pH range. Biochemistry. 2007 Mar 6;46(9):2398-410. Epub 2007 Feb 6. [PubMed:17279774 ]
  2. Ahmed TA, Buzzelli MD, Lang CH, Capen JB, Shumate ML, Navaratnarajah M, Nagarajan M, Cooney RN: Interleukin-6 inhibits growth hormone-mediated gene expression in hepatocytes. Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1793-803. Epub 2007 Mar 29. [PubMed:17395896 ]
  3. Moderscheim TA, Gorba T, Pathipati P, Kokay IC, Grattan DR, Williams CE, Scheepens A: Prolactin is involved in glial responses following a focal injury to the juvenile rat brain. Neuroscience. 2007 Mar 30;145(3):963-73. Epub 2007 Feb 20. [PubMed:17317019 ]
  4. Cunningham BC, Bass S, Fuh G, Wells JA: Zinc mediation of the binding of human growth hormone to the human prolactin receptor. Science. 1990 Dec 21;250(4988):1709-12. [PubMed:2270485 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on April 30, 2016 02:28